BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies.

CDKN2A 癌症研究 肺癌 克拉斯 ROS1型 医学 融合基因 癌症 CDKN2B公司 黑色素瘤 V600E型 分子反转探针 结直肠癌 肿瘤科 基因 内科学 腺癌 突变 生物 遗传学 基因分型 基因型
作者
Venkataprasanth P. Reddy,Laurie M. Gay,Julia A. Elvin,Jo‐Anne Vergilio,James Suh,Shakti Ramkissoon,Sugganth Daniel,Eric A. Severson,Siraj M. Ali,Alexa B. Schrock,Jon Chung,Garrett M. Frampton,David Fabrizio,Phil Stephens,Vincent A. Miller,Jeffrey S. Ross
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:35 (15_suppl): 9072-9072 被引量:12
标识
DOI:10.1200/jco.2017.35.15_suppl.9072
摘要

9072 Background: Although far less common than BRAF V600E base substitutions (subs) classically associated with melanomas and colorectal carcinomas, BRAF subs occur in 1-2% of non-small cell lung cancer (NSCLC). BRAF fusions are emerging treatment targets for Spitzoid melanomas and other solid tumors. The frequency of BRAF fusions and targeting potential in NSCLC has not been widely described. Methods: Hybridization capture-based comprehensive genomic profiling (CGP) was performed on 17,128 NSCLC FFPE samples sequenced to a mean coverage depth of > 550X for up to 315 cancer-related genes plus 37 introns from 19 genes frequently rearranged in cancer. Genomic alterations (GA) included short variant (SV) base subs and insertions/deletions, copy number alterations, and rearrangements/fusions. Tumor mutational burden (TMB; mut/Mb) was calculated on up to 1.1 Mb of sequenced DNA. Results: BRAF fusions were identified in 42/17,128 (0.2%) NSCLC profiled. Median patient age was 67 (range 44-93 yrs). Of the BRAF fusion positive NSCLC, 55% were female. Biopsies were obtained from primary lung tumor (48%) and metastatic sites (52%). The most frequent 5’ partners were AGK, DOCK4, and TRIM24. Multiple novel BRAF fusions were identified. The genes most frequently co-altered with BRAF fusions were TP53(67%), CDKN2A(31%), EGFR (29%) and CDKN2B (26%). Overall TMB in the BRAFfusion positive cohort was low (median 3.8 mut/Mb), although 3/42 cases (7%) had > 20 mut/Mb. Of the BRAF fusion driven NSCLC, 10 cases (24%) featured EGFR SV alterations. Two BRAF fusion/ EGFR SV cases featured primary exon 19 deletion and T790M mutation. Examples of BRAF fusion driven NSCLC responding to a combination of BRAFand MEK inhibitors (MEKi) will be presented. Conclusions: NSCLC BRAF fusions are a rare GA that may be associated with acquired resistance in a subset of EGFR-mutated NSCLC progressing on anti- EGFR TKI therapies. Given clinical evidence for the activity of targeted therapy approaches, molecular eligibility for clinical trials of MEKi should include these variants. The clinical evidence for responsiveness of BRAF fusion driven NSCLC provides an opportunity to personalize treatments and improve clinical outcomes for patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Gtpangda完成签到 ,获得积分10
3秒前
biubiu完成签到 ,获得积分10
6秒前
王豆豆发布了新的文献求助10
7秒前
7秒前
duan完成签到,获得积分10
8秒前
Retrose应助研友_8Raw2Z采纳,获得10
8秒前
10秒前
11秒前
小富发布了新的文献求助10
14秒前
huhu完成签到 ,获得积分10
15秒前
15秒前
闪闪路人发布了新的文献求助10
18秒前
高贵紫丝发布了新的文献求助10
19秒前
20秒前
NexusExplorer应助CD5522采纳,获得10
20秒前
21秒前
li发布了新的文献求助10
22秒前
22秒前
24秒前
有风塘发布了新的文献求助10
25秒前
SSS水鱼发布了新的文献求助10
26秒前
深情安青应助吃吃货采纳,获得10
26秒前
Jerry完成签到 ,获得积分10
27秒前
30秒前
wuuu_ruby完成签到 ,获得积分10
32秒前
专通下水道完成签到,获得积分10
33秒前
34秒前
orixero应助这辈子瘦不了采纳,获得30
35秒前
刚刚好完成签到,获得积分10
36秒前
Dandelion完成签到,获得积分10
36秒前
万能图书馆应助闪闪路人采纳,获得10
36秒前
CD5522发布了新的文献求助10
37秒前
Ruoru发布了新的文献求助10
37秒前
37秒前
领导范儿应助dongli0616采纳,获得20
39秒前
CipherSage应助王豆豆采纳,获得10
40秒前
吃吃货发布了新的文献求助10
40秒前
42秒前
小蘑菇应助科研通管家采纳,获得10
42秒前
烟花应助科研通管家采纳,获得10
43秒前
高分求助中
Effect of reactor temperature on FCC yield 1500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Uncertainty Quantification: Theory, Implementation, and Applications, Second Edition 800
The Healthy Socialist Life in Maoist China 600
Production Logging: Theoretical and Interpretive Elements 555
Mesopotamian Divination Texts: Conversing with the Gods 500
The AASM International Classification of Sleep Disorders – Third Edition, Text Revision (ICSD-3-TR) 490
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3280029
求助须知:如何正确求助?哪些是违规求助? 2918212
关于积分的说明 8389196
捐赠科研通 2589264
什么是DOI,文献DOI怎么找? 1410666
科研通“疑难数据库(出版商)”最低求助积分说明 657748
邀请新用户注册赠送积分活动 638994